ANDA 202864, held by Hospira. Ampicillin Sodium.
As of Nov 21, 2026, ANDA 202864 (Ampicillin Sodium), held by Hospira, was first approved by FDA on Sep 4, 2015, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 4, 2015 | Original application | Approved |
| Ampicillin SodiumEQ 250MG BASE/VIAL · injectable;injection | Ampicillin Sodium | Discontinued |
| Ampicillin SodiumEQ 500MG BASE/VIAL · injectable;injection | Ampicillin Sodium | Discontinued |
| Ampicillin SodiumEQ 1GM BASE/VIAL · injectable;injection | Ampicillin Sodium | Discontinued |
| Ampicillin SodiumEQ 2GM BASE/VIAL · injectable;injection | Ampicillin Sodium | Discontinued |
| Feb 15, 2018 | Supplement 1Labeling · Standard review | Approved | None posted |
| Sep 4, 2015 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters